A Southwest Oncology Group study

TLDR

The Southwest Oncology Group conducted a trial of VM‑26 (teniposide) in patients with advanced gastric cancer. VM‑26 was administered at 60 mg/m² IV over 30–45 min daily for 5 days every 21 days to 21 eligible patients with measurable disease and ECOG 0–2. Among 21 patients, 9.5 % achieved partial responses, median survival was 3.8 months, and 62 % experienced severe toxicity—including two drug‑related deaths and seven with grade 4 granulocytopenia—making the modest activity comparable to etoposide but unlikely to justify further trials.

Abstract

Summary The Southwest Oncology Group conducted a trial of VM-26 (teniposide) in patients with advanced gastric cancer. VM-26 60 mg/m 2 IV infusion over 30-45 minutes was given daily for 5 days every 21 days. Twentyone eligible patients with measurable disease and a SWOG performance status of 0-2 were analyzed for response and toxicity. Partial responses were seen in 2 of the 21 eligible patients (9.5 %). Median survival was 3.8 months. Severe or life-threatening toxicity was observed in 13/21 (62%) patients. This included two drug related deaths related to neutropenic sepsis and seven other patients with grade 4 granulocytopenia (< 500/mmJ). Liver dysfunction and hypotension were seen less often and were not dose limiting. Although the modest activity seen was comparable to that of VP-16 (etoposide) as a single agent, the hematologic toxicity observed in this trial would likely preclude further trials of VM-26 (teniposide) in advanced gastric cancer.